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Objective:  For  extended-release  drugs  with  multi-compartment  kinetics,  such  as  topiramate,  effective
half-life  (t1/2eff) may  be a more  clinically  relevant  parameter  than  elimination  half-life  (t1/2z). Using  top-
iramate  as a real-life  example,  the objective  was to compare  these  half-life  values  for  immediate-  and
extended-release  topiramate  (TPM-IR  and  USL255,  respectively)  to  understand  how  drug  pharmacoki-
netics  may  impact  drug  dosing  recommendations.
Methods:  The  t1/2z and  t1/2eff for USL255  and  TPM-IR  were  compared  using  data  from  a phase  I study  (N  =  36)
of  200  mg  USL255  administered  once  daily  (QD)  or TPM-IR  twice  daily  (BID);  effect  of  sampling  duration
on  t1/2z was  investigated.  To  further  explore  the relationship  between  half-life  and  dosing,  steady-state
PK  was  simulated  for USL255  and TPM-IR.
Results:  As  previously  reported,  mean  t1/2z was  similar  between  USL255  (80.2 h)  and  TPM-IR  (82.8  h);  TPM-
IR t1/2z was  ∼4 times  longer  than  reported  in the Topamax  label  (21  h).  In contrast,  USL255  displayed  a
1.5  fold  longer  t1/2eff (55.7  vs  37.1  h  for TPM-IR).  When  t1/2z was  calculated  from  48 to  336  h, values
ranged from  28.8 to  82.8 h. Simulated  steady-state  PK profiles  of  USL255  QD  exhibited  reduced  plasma
fluctuations  during  a dosing  interval  vs  TPM-IR  QD  or BID.
Significance:  As  expected  for the  same  moiety,  t1/2z of  USL255  and  TPM-IR  were  similar;  however,  the
longer  t1/2eff for USL255  better  approximates  differences  in recommend  dosing  (QD  USL255  vs  BID  TPM-
IR).  Further,  sampling  duration  impacted  t1/2z, diminishing  its predictive  value  for  determining  dose
regimens;  sampling-time  differences  may  also  explain  t1/2z discrepancy  between  TPM-IR  here  versus
Topamax  label.  As  expected,  steady-state  simulations  confirm  that  although  TPM-IR  has  a long  t1/2z,
taking  TPM-IR  QD  would  lead to large plasma  fluctuations.  These  data  demonstrate  that  t1/2z may  be
less  clinically  meaningful  than  t1/2eff, and using  t1/2z for some  drugs  may  lead  to erroneous  conclusions
regarding  dosing  regimens.
©  2016  The  Author(s).  Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Appropriate interpretation of pharmacokinetic (PK) data is cru-
cial when optimizing antiepileptic drug (AED) therapy. It is equally
important that one not misapply either pharmacokinetic data, or
the underlying mathematical principles of PK when constructing
∗ Corresponding author at: University of Wisconsin School of Pharmacy, 777 High-
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an individualized AED dosing regimen. One of the oldest, and most
fundamental concepts in pharmacotherapy is that of drug half-life
(t1/2). The simple definition of t1/2 is the time interval over which
the amount of drug in the body is decreased by one-half. A common
misconception is that t1/2 is synonymous with clearance, which is
not completely accurate. In fact, t1/2 is a hybrid parameter that takes
into account drug clearance as well as its volume of distribution (ie,
drug distribution between plasma and the rest of the body after dos-
ing). Therefore, a better way of viewing t1/2 is that it is a predictor
of drug accumulation and fluctuation in plasma concentration.
Clinicians may use t1/2 to guide them in individualizing dosage
regimens for patients. Understanding t1/2 is particularly important
when determining dosing intervals for chronically-administered
http://dx.doi.org/10.1016/j.eplepsyres.2016.10.020
0920-1211/© 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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drugs, as dosing adjustments may  impact a drug’s systemic expo-
sure (ie, area under the concentration-time curve [AUC]) and
plasma fluctuations. For example, if a drug is administered at a
steady-state frequency equal to its t1/2, then AUC during that dos-
ing interval will be twice that seen following a single dose (Sahin
and Benet, 2008); this is due to drug accumulation over time as a
repeated dose is given prior to disappearance of the previous dose.
Giving a drug more frequently than its t1/2 will result in more drug
accumulation, with the opposite occurring if that drug is given less
frequently than the t1/2 (Grover and Benet, 2011). With regards to
plasma fluctuations, dosing a drug more frequently than its t1/2 will
result in a flatter plasma concentration-time curve (ie, less fluctua-
tion) than if that same daily dose were being given less frequently
(Grover and Benet, 2011).
Though half-life is a key pharmacokinetic parameter in deter-
mining drug dosing, it is important to note that drugs may  exhibit
multiple half-lives, depending on how they distribute into tissues
throughout the body following dosing. As such, different methods
can be used to calculate a drug’s half-life. In practice, clinicians will
often use terminal elimination half-life (t1/2z) to guide drug dosing,
as this is the most widely published half-life value and the one
typically reported in prescribing information. The t1/2z for a drug
is defined as drug elimination during the terminal phase, which is
the final elimination phase following drug absorption and redistri-
bution into body tissues.
For drugs with simple linear pharmacokinetics, t1/2z may  be
an accurate measure of a drug’s half-life. However, for drugs with
slower absorption, multi-compartment distribution into different
tissues, and multi-exponential disposition, t1/2z may  be a poor pre-
dictor of drug accumulation and fluctuation. This is illustrated in
Fig. 1A, which depicts a hypothetical plasma concentration-time
profile for a drug that distributes into multiple compartments. As
t1/2z describes drug elimination during the terminal phase (after
drug absorption and distribution has entirely completed), t1/2z may
only describe a very small fraction of the plasma concentration-
time curve (Bialer and Soares-da-Silva, 2012). Therefore, t1/2z will
probably not describe concentration decline during a dosage inter-
val for drugs with more complex absorption and distribution
characteristics, such as extended-release formulations that are
specifically designed to have a slower absorption profile. Another
limitation of t1/2z is that the value can be impacted by PK assay
methods, including sampling duration, assay sensitivity, and sam-
pling frequency. For example, sampling duration (ie, the duration of
time over which plasma samples are taken) can change the phase
when half-life is measured, thereby impacting the resulting t1/2z
value (Fig. 1A).
Given that most antiepileptic drugs (AEDs) will likely display
multi-compartment kinetics, which half-life should the clinician
use? If our clinical objective is to dose a drug that can be given as
infrequently as possible, with minimal plasma concentration fluc-
tuation and consistent exposure during the dosage interval, then
use of the commonly accepted and published value of t1/2z may
be incorrect for many AEDs. Indeed, using this value may  result in
suboptimal dosing predictions (Sahin and Benet, 2008). Therefore,
a more clinically relevant half-life measure may be effective half-
life (t1/2eff), which describes the rate of drug loss across the entire
dosing interval.
Unlike t1/2z, which is calculated using the slope of the last drug
elimination phase following single-dose administration (Fig. 1A;
Eq. (1)), t1/2eff takes into consideration the entire concentration-
time profile of a drug. The t1/2eff is calculated based on both the
drug-dosing interval and drug accumulation over time following
multiple-dose administration (Fig. 1B; Eq. (2)) (Boxenbaum and
Battle, 1995). As a result, t1/2eff is expected to be less affected by
sampling duration compared with t1/2z, and its calculation only
requires sampling over the dosing interval following a single dose
and at steady state. Thus, using t1/2eff to guide dosing may  be partic-
ularly beneficial when long-term maintenance of therapeutic levels
is required.
Overall, the use of t1/2eff in lieu of t1/2z may be particularly
beneficial for extended-release AEDs with multi-compartment
kinetics. Topiramate (TPM) is one such agent; Gidal and Lensmeyer
demonstrated that TPM partitions in a saturable manner into ery-
throcytes (Gidal and Lensmeyer, 1999). The release of TPM from this
high-affinity red blood cell compartment—presumably to carbonic
anhydrase—likely contributes to reduced apparent oral clearance
and volume of distribution at low concentrations (Shank et al.,
2005). These properties of TPM make it an ideal candidate to com-
pare the clinical utility of these two  half-life measures.
Using TPM as a real-life example, the objective of this
manuscript is to understand how the pharmacokinetics of
immediate-release (IR) and extended-release (XR) formulations
may  impact drug dosing recommendations. First, the t1/2eff and
t1/2z of IR and XR TPM will be compared to demonstrate how both
formulation differences and methodology impact half-life values.
Additionally, steady-state profiles will be simulated to understand
how varying drug dosing (ie, once- vs twice-daily dosing) impacts
the pharmacokinetics of IR versus XR formulations. Together, the
use of TPM—an AED with IR and XR formulations—will demonstrate
which half-life measure may be more clinically-useful in determin-
ing appropriate dosing intervals.
2. Methods
2.1. Comparison of elimination and effective half-Lives for
USL255 and TPM-IR
The two TPM formulations evaluated were once-daily (QD)
USL255, Qudexy® XR (topiramate) extended-release capsules
(Upsher-Smith Laboratories, Inc. (Qudexy®, 2015)) and twice-daily
(BID) IR topiramate (TPM-IR; Topamax®; Janssen Pharmaceuticals
(Topamax®, 2009)). Half-life values were assessed from a phase
I, randomized (N = 36), open-label, crossover study of single-dose
USL255 200 mg and 2 doses of TPM-IR 100 mg  dosed every 12 h
(Lambrecht et al., 2011). The t1/2z and t1/2eff for USL255 and TPM-
IR were previously calculated (Eqs. (1) and (2)) (Lambrecht et al.,
2011). In brief, t1/2z is calculated by dividing the natural log of 2 by
the slope of the last phase (z), which is dependent on the blood
sampling duration used for PK analyses (Fig. 1, Eq. (1)).
t1/2z = ln2/z (1)
In contrast, t1/2eff is calculated based on dosing interval
() and drug accumulation over time following multiple-dose
administration (ie, drug accumulation index [Rac = steady-state
AUC0-/single-dose AUC0-]; Eq. (2)).
t1/2eff =  ∗ ln2/ln[Rac/(Rac − 1)] (2)
To determine how the plasma sampling duration for PK calcula-
tions can impact half-life, t1/2z was  calculated using data from the
48, 72, 168, 264, and 336 h PK sampling times of the phase I study
for both USL255 and TPM-IR. Detailed information regarding par-
ticipants and topiramate analyses are described in Lambrecht et al.
(Lambrecht et al., 2011).
2.2. Simulated steady-state pharmacokinetic profiles for USL255
and TPM-IR
Simulations were used to predict steady-state plasma
concentration-time profiles of USL255 administered QD and
TPM-IR 200 mg  administered QD or BID; approved dosing is QD
for USL255 and BID for TPM-IR (Qudexy®, 2015; Topamax®, 2009).
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Fig. 1. Hypothetical Profiles Used to Calculate Elimination and Effective Half-Lives.
(A)  Illustrated here is a hypothetical plasma concentration-time profile following a single dose of a 3-compartment drug. In the  phase, a rapid decrease in plasma levels is
due  to drug distribution from circulation (central compartment) into body tissues (peripheral compartments); this phase ends with pseudo-equilibrium of drug concentration
between the central and peripheral compartments. The  phase describes a slower decrease in plasma drug levels due to drug metabolism and excretion from the body. The
  phase can occur later when tissue-bound drug is released into circulation then eliminated from the body; the  phase may be associated with very small and insignificant
amount of drug distribution. The slope of the last phase (z) is used to calculate t1/2z. In this example, the  phase would be used, as the sampling duration extended to 24 h.
If  the sampling duration was  only 12 h, the  phase would be used to calculate t1/2z. Together, this figure illustrates how sampling duration may impact elimination half-life,
and  result in t1/2z estimates not being predictive of drug accumulation.
(B) Depicted is a hypothetical drug plasma accumulation following multiple doses of a drug dosed every 12 h. This graph describes the variables used to calculate t1/2eff: drug
dosing  interval () and drug accumulation index (Rac; steady-state AUC0-/single-dose AUC0-). AUC (area under the plasma concentration-time curve), is represented by the
shaded  boxes. In this hypothetical example,  = 12 h and Rac = 2. Figure modified from Boxenbaum H and Battle M.  Effective half-life in clinical pharmacology. J Clin Pharmacol
1995;  35:763–766 (Boxenbaum and Battle, 1995).
For USL255, a 2-compartment population PK model with sigmoid
absorption and first-order elimination was developed from data
obtained from 158 healthy male and female participants enrolled
in four phase I studies (Bialer et al., 2013; Clark et al., 2014, 2016;
Lambrecht et al., 2011). Covariate effects included allometric
effects of weight on apparent oral clearance of topiramate (CL/F)
and on apparent volume of distribution within the central com-
partment, and the effects of creatinine clearance on CL/F. TPM-IR
was simulated using a modified 2-compartment linear population
PK model with first order absorption as previously described
(Girgis et al., 2010; Marathe, 2010). Covariate effects of weight on
CL/F in the TPM-IR model were included.
Using the models described above, steady-state concentration-
time profiles of USL255 QD and TPM-IR 200 mg/day QD or BID
were simulated in a virtual population of 250 healthy individ-
uals using NOMMEM® (ICON, Ellicott City, MD), and validated
against observed data (Bialer et al., 2013). The virtual participant
population for each formulation was  generated through random
re-sampling of participant characteristics in the USL255 model
development dataset, keeping weight and creatinine clearance val-
ues together in the same individual. Steady-state simulations were
used to compare the minimum observed drug plasma concentra-
tion (Cmin), maximum observed drug plasma concentration (Cmax),
and fluctuation index ([Cmax − Cmin]/Cavg*100, where Cavg is the
average drug plasma concentration) of USL255 and TPM-IR.
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3. Results
3.1. Comparison of terminal and effective half-lives for USL255
and TPM-IR
The half-lives of USL255 and TPM-IR were evaluated in a prior
phase I study of 36 healthy volunteers following a single dose
of 200 mg  USL255 QD and 200 mg  TPM-IR BID (Lambrecht et al.,
2011). As expected, the mean t1/2z was similar for USL255 and TPM-
IR (80.2 h vs 82.8 h (Lambrecht et al., 2011)), despite differences
in drug formulations and dosing recommendations. In contrast,
the t1/2eff for USL255 was 1.5 fold longer than TPM-IR (55.7 h vs
37.1 h (Lambrecht et al., 2011)). This marked difference in t1/2eff
between an immediate- and extended-release formulation is not
unexpected, as effective half-life takes into account drug accumu-
lation over the dose interval. Further, t1/2eff values were shorter
than t1/2z for both USL255 and TPM-IR (55.7 vs 80.2 h for USL255
and 37.1 vs 82.8 h for TPM-IR, respectively).
3.2. Effect of sampling duration on terminal half-life values
For TPM-IR, mean terminal half-life of 82.8 h (Lambrecht et al.,
2011), is almost 4-times longer than the 21 h value reported in the
TPM-IR prescribing information (Topamax®, 2009). Because termi-
nal half-life is dependent upon assay methodology, we  investigated
sampling duration as a factor for this large difference. Thus, t1/2z
was calculated for USL255 and TPM-IR using different sampling
durations from the dataset (Fig. 2). As sampling duration increased
from 48 to 336 h, t1/2z increased for both USL255 and TPM-IR, inde-
pendent of the formulation, with large ranges in value (USL255,
35.6–80.2 h; TPM-IR, 28.8–82.8 h). Interestingly, the 28.8 h half-life
observed for TPM-IR at 48 h (Fig. 2) is in alignment with the 21 h
half-life reported in the prescribing information, which was based
upon a 32 h sampling time (Topamax®, 2009).
3.3. Simulated steady-state pharmacokinetic profiles for USL255
and TPM-IR
The simulated steady-state plasma concentration-time profiles
for a typical individual receiving 200 mg/day USL255 or TPM-IR
administered as a single 200 mg  dose (QD) or two 100 mg  doses
(BID) are shown in Fig. 3. Validity of this simulation was supported
by the similarity between observed steady-state phase I data of
200 mg/day USL255 QD and TPM-IR BID administered for 14 days
(Bialer et al., 2013) and the simulated steady-state profiles. Based
upon these simulations it is evident that although TPM-IR has a
long t1/2z (>80 h), QD dosing based upon t1/2z would lead to large
plasma fluctuations.
Evaluation of the recommended dosing regimen for USL255
and TPM-IR showed that mean predicted fluctuation index for
USL255 QD was 18% lower than TPM-IR BID (0.23 vs 0.28), with
a 47% decrease in the maximum fluctuation index (0.67 USL255
QD vs 1.27 TPM-IR BID). This difference is not unexpected, due
to the greater predicted variability in Cmin and Cmax concentra-
tions with TPM-IR BID compared with USL255 QD (Fig. 3; Table 1).
Higher minimum plasma concentration for USL255 may  have been
a primary reason for this difference in fluctuation index, as mean
predicted Cmin for USL255 QD was 7.4% higher compared with TPM-
IR BID, with little difference in mean predicted Cmax (1.5% higher
for USL255 vs TPM-IR; Table 1).
Though the comparison above included two drugs with different
formulations (XR vs IR) and different dosing schedules (BID vs QD),
similar trends are expected when keeping either formulation or
dosing schedule consistent. For example, dosing XR and IR formu-
lations on a similar schedule would be predicted to result in large
fluctuation index differences; as expected, USL255 QD had a 65%
Table 1
Predicted steady-state PK parameters of USL255 and TPM-IR administered once or
twice daily.
USL255 TPM-IR
QD BID QD
Cmin, g/mL
Mean (SD) 6.05 (1.53) 5.63 (1.74) 4.73 (1.99)
Median 5.96 5.62 4.51
Range 3.28–11.8 1.65–11.2 1.07–12.9
Cmax, g/mL
Mean (SD) 7.60 (1.72) 7.48 (2.39) 9.04 (3.59)
Median 7.44 7.04 8.39
Range 4.20–13.8 2.14–16.8 1.68–25.7
Fluctuation Index
Mean (SD) 0.23 (0.09) 0.28 (0.21) 0.66 (0.46)
Median 0.21 0.21 0.52
Range 0.06–0.67 0.07–1.27 0.08–2.42
Abbreviations: BID, twice daily; Cmax, maximum plasma concentration; Cmin, mini-
mum  plasma concentration; max, maximum; min, minimum; PK, pharmacokinetic;
QD, once daily; SD, standard deviation; TPM-IR, immediate-release topiramate;
USL255, extended-release topiramate.
lower mean predicted fluctuation index versus TPM-IR QD (0.23 vs
0.66; Fig. 3; Table 1). Similarly, dosing the same formulation more
frequently would be predicted to reduce plasma fluctuations; as
expected, BID administration of TPM-IR resulted in a 47% decrease
in the mean predicted fluctuation index compared with QD dosing
(0.28 vs 0.66; Fig. 3; Table 1). The reduced plasma fluctuation with
BID dosing was due to a 19% higher mean predicted Cmin and 17%
lower mean predicted Cmax versus QD dosing.
4. Discussion
Selection of an appropriate dosing interval is an important clin-
ical decision. While many clinicians and clinical scientists have
been taught that elimination half-life (t1/2z) is the most useful
parameter to guide dosing decisions (Sahin and Benet, 2008),
this half-life value may  not optimally characterize the steady-
state concentration-time profile for many drugs (Dutta and Reed,
2006). A more appropriate parameter to predict drug accumulation
and describe elimination at steady state may  be effective half-life
(t1/2eff), which considers the entire plasma concentration-time pro-
file of the drug and may  better reflect total clearance (Boxenbaum
and Battle, 1995). This may  be particularly the case in situations
where clinicians opt to use newer extended-release formulations
of existing agents.
A goal of this manuscript was to use TPM as a real-life example
to understand how drug PK—including half-life—may impact drug
dosing recommendations. Results from these analyses suggest that
half-life measures can be influenced by drug formulation (ie, XR and
IR) and methodology (ie, PK sampling time). This was confirmed
with observed data from TPM demonstrating that t1/2z is insensitive
to formulation differences and varies depending on drug sampling
time whereas t1/2eff may better approximate differences between
XR and IR TPM.
When determining the impact of drug formulation on PK, one
might think that an extended- and immediate-release formulation
of the same active moiety would have different half-life values.
However, the t1/2z for USL255 and TPM-IR are nearly identical
(80.2 vs 82.8 h, respectively), and no large difference in t1/2z was
observed between these 2 formulations when sampling time was
kept consistent (Fig. 2). This similar t1/2z for USL255 and TPM-IR
may  lead to the incorrect assumption that changes in plasma con-
centration over 24 h are similar between XR and IR formulations
or that IR drugs may  be dosed less frequently. In contrast, the 1.5-
fold higher t1/2eff for USL255 versus TPM-IR (55.7 vs 37.1 h) better
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Fig. 2. Impact of Pharmacokinetic Sampling Duration on Elimination Half-Life of 200 mg USL255 and TPM-IR.
t1/2z calculated at each sampling duration (black arrows) for 200 mg/day USL255 and TPM-IR is presented under the concentration-time profile for both topiramate formu-
lations.  Linear scale is shown in panel A and log scale shown on panel B. Samples for TPM-IR were taken following the 2nd BID dose (eg, 48 h equals 36 h post 2nd dose,
72  h equals 60 h post 2nd dose, etc). Figure was modified from Lambrecht LJ et al. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release
formulation of topiramate. Epilepsia 2011;52(10):1877–83 (Lambrecht et al., 2011).
Abbreviations: BID, twice daily; QD, once daily; t1/2z; elimination half-life; TPM-IR, immediate-release topiramate; USL255, extended-release topiramate.
approximates the difference in recommend dosing between the
2 formulations (QD vs BID, respectively). Similar results for other
AEDs also have demonstrated that t1/2eff may  be more clinically
meaningful than t1/2z. Dutta and Reed demonstrated that although
valproic acid has a t1/2z of 12–16 h, the t1/2eff of divalproex-ER over a
dosage interval was in fact 40 h (due to its prolonged drug release),
supporting its once-per-day administration (Dutta and Reed, 2006).
Likewise, for the AED eslicarbazepine acetate, t1/2eff corresponds
well with its once-daily dose interval. Based upon its absorption
rate as well as metabolite formation rate and dosage interval,
eslicarbazepine accumulation ratio translated into an t1/2eff for esli-
carbazepine of 20–24 h, or about twice as long as its t1/2z (Bialer and
Soares-da-Silva, 2012).
In addition to being unaffected by drug formulation differences,
t1/2z can also be impacted by clinical methodology. As described
above, the 82.8-h t1/2z reported for TPM-IR (Lambrecht et al., 2011)
is almost 4-times longer than the 21-h value reported in the TPM-IR
label (Topamax®, 2009). Though the half-life value from Lambrecht
et al. may  seem contradictory to the Topamax prescribing infor-
mation, this discrepancy in t1/2z is likely due to methodology and
not due to an actual difference in half-life. For example, the sensi-
tivity of the PK assay was increased for Lambrecht and colleagues
versus the Topamax prescribing information (10 ng/mL lower limit
of quantification [LLOQ] vs 500 ng/mL LLOQ, respectively); fur-
ther, Lambrecht et al. had a longer sampling duration (336 vs 32 h,
respectively). To demonstrate how sampling time can impact t1/2z,
TPM-IR and USL255 were evaluated at various time points. As sam-
pling duration increased from 48 to 336 h, the t1/2z also increased
from approximately 30 to 80 h (Fig. 2). It is important to note that
this large impact of sampling time on t1/2z is not a universal fea-
ture for all drugs; for TPM, its multi-compartment PK may make it
more sensitive to sampling time compared with a drug that does
not distribute into multiple tissue compartments (see Fig. 1A for a
hypothetical example on how sampling time may impact t1/2z).
Taken together, these data suggest that t1/2z may not accurately
represent a clinically meaningful elimination or accumulation esti-
mate of an extended-release drug, and use of t1/2z may result in an
inaccurate prediction of the appropriate dosing interval.
A limitation of these analyses is the evaluation of PK in healthy
individuals and not patients with epilepsy; as such, specific factors
that may  influence PK may  not be represented (eg, concomitant
use of cytochrome inducers or inhibitors). FDA guidance often rec-
ommends PK analyses in healthy individuals, which may limit
confounding factors, and data from healthy individuals are often
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Fig. 3. Mean Predicted Steady-State Plasma Topiramate Concentrations of USL255 and TPM-IR Administered QD or BID.
Simulated steady state based on mean predicted plasma concentration-time profiles for 200 mg/day USL255 and TPM-IR once- or twice-daily are shown.
Abbreviations: BID, twice daily; QD, once daily; TPM-IR, immediate-release topiramate; USL255, extended-release topiramate.
used in modeling analyses to evaluate drug PK. Further, results
from these analyses were not intended to serve as direct clinical
outcome data. A detailed comparison of t1/2z and t1/2eff—using TPM
as a real-life example—was used to illustrate how formulation and
methodological differences may  impact half-life values, which has
implications in patient care.
For example, in cases where clinicians choose to implement
a dosing schedule that differs from the approved dosing recom-
mendations of a given drug, understanding half-life is particularly
important. For patients who are already on concomitant BID drugs,
some clinicians may  recommend taking the same total daily dose
of a QD drug (with a long half-life) twice daily to potentially reduce
plasma fluctuations and simplify the overall drug regimen. Con-
versely, a clinician may  assume that a BID drug with an ∼24-h
half-life could be administered QD. For example, the 21-h reported
t1/2z for TPM-IR (Topamax®, 2009) may  be interpreted to mean QD
dosing is acceptable. However, QD dosing may  not be optimal based
on the predicted steady-state profile of TPM-IR, which showed
increased plasma fluctuations compared with TPM-IR BID (Fig. 3).
These data, using TPM as an example, underscore the importance
of understanding the clinical relevance of half-lives reported in a
drug’s prescribing information. Additionally, while half-life may  be
one parameter used to guide dosing, assessing the entire steady-
state profile may  provide additional information when optimizing
a dosing regimen.
It is important to note that neither t1/2z nor t1/2eff for USL255 and
TPM-IR are identical to recommended dosing intervals for these
drugs. This is because half-life alone may  not provide all of the
information necessary to construct an appropriate dosing regimen,
as additional pharmacodynamic effects of a drug (eg, therapeu-
tic index and receptor binding affinity/duration of binding) may
influence drug distribution. Additionally, drugs can be dosed more
frequently than recommended by half-life values, as dosing may  be
optimized to decrease fluctuations in plasma concentrations.
USL255 was developed to provide relatively consistent plasma
drug concentrations across a 24-h dosing interval with reduced
fluctuations compared with TPM-IR (Bialer et al., 2013). This is sup-
ported by the steady-state simulations shown here, which revealed
that USL255 QD had a smaller fluctuation index and higher Cmin
than TPM-IR QD or BID (Fig. 3). The mean predicted fluctuation
index for USL255 QD was reduced by 18% compared with TPM-
IR BID, which is slightly lower than the observed 26% decrease
in fluctuation index with USL255 QD versus TPM-IR BID follow-
ing steady-state dosing in healthy volunteers (Bialer et al., 2013).
This difference may  be due in part to limitations in our methodol-
ogy; while data from the Bialer et al. study were used to estimate
t1/2eff for USL255 and TPM-IR, the models used here were from the
literature. Therefore, the profiles in this analysis were developed
using 2 different data sets (ie, not the same participants).
The predicted steady-state profiles for USL255 and TPM-IR pro-
vide a better understanding of XR versus IR topiramate PK, which
may  be considered when determining drug choice and dosing. In
general, XR AEDs tend to have reduced plasma fluctuations and
flatter plasma concentration-time curves than their IR counter-
parts (Pellock et al., 2004), a pattern that also was observed for
USL255 and TPM-IR. A flatter steady-state curve for XR AEDs may  be
favorable for patients who require dosing adjustments, particularly
increased doses, to maintain seizure control without precipitating
any adverse events associated with peak concentrations (Pellock
et al., 2004).
5. Conclusions
The commonly referenced elimination half-life (t1/2z) may  not
be adequate or appropriate in many circumstances. Effective half-
life, or t1/2eff, may  indeed be more clinically relevant as it takes into
consideration the entire concentration-time profile of a drug. This
is particularly true when comparing dosing requirements between
immediate and extended-release product formulations. However,
half-life is not the only parameter used to determine dosing regi-
mens. The importance of recommended dosing from prescribing
information is illustrated by the simulations of TPM-IR; while
once-daily dosing may  seem appropriate with its long reported
half-life, doing so may  result in large plasma fluctuations. Together
with the comparison of t1/2eff and t1/2z, these data underscore the
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importance of understanding half-life measures, and may  improve
clinicians’ understanding of dosing regimens.
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